Perception of urinary biomarker tests among patients referred with suspected urological malignancy

Bullock, Nicholas, Mubarak, Mohamed, Morris, Ceri, Clements, Colette, Geere, Clare, Tidball, Sarah, Bois, Elizabeth, Davies, Michael, Featherstone, Jonathan, Narahari, Krishna, Weeks, Ian ORCID: https://orcid.org/0000-0002-6362-2929 and Kynaston, Howard 2023. Perception of urinary biomarker tests among patients referred with suspected urological malignancy. BJUI Compass 10.1002/bco2.234

PDF - Published Version Available under License Creative Commons Attribution. Download (551kB)

Abstract

Objective To determine the acceptability of a non-invasive urinary biomarker test in place of conventional flexible cystoscopy for the diagnosis of bladder cancer in patients referred to a Rapid Access Haematuria Clinic (RAHC) with suspected urological malignancy. Patients and methods Patients attending a RAHC were recruited to a prospective observational study evaluating a novel urinary biomarker (URO17™) for the detection of bladder cancer and invited to complete a two-part structured questionnaire. Questions related to demographics, attitudes towards conventional cystoscopy and the minimal acceptable sensitivity (MAS) at which a urinary biomarker would be considered an alternative to flexible cystoscopy both before and after undergoing the procedure. Results A total of 250 patients completed the survey; the majority of whom were referred with visible haematuria (75.2%). One hundred seventy-one (68.4%) would be willing to accept a urinary biomarker in place of cystoscopy, with 59 (23.6%) expressing preference for the biomarker with a MAS as low as 85%. Conversely, 74 patients (29.6%) would not be willing to accept a urinary biomarker, regardless of its sensitivity. A significant number of patients reported a change in MAS after undergoing cystoscopy, with 80 (32.0%) and 16 (6.4%) increasing and decreasing the required value respectively (P = 0.001). The greatest increase was seen in the proportion of patients unwilling to accept a urinary biomarker regardless of its sensitivity, rising from 29.6% to 38.4%. Conclusions Although many patients attending a RAHC would be willing to accept a urinary biomarker test in place of conventional flexible cystoscopy for the detection of bladder cancer, effective patient, public and clinician engagement will be necessary at all stages of implementation if it is to become an established component of the diagnostic pathway.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Publisher:	Wiley Open Access
ISSN:	2688-4526
Date of First Compliant Deposit:	5 April 2023
Date of Acceptance:	5 March 2023
Last Modified:	03 May 2023 14:36
URI:	https://orca.cardiff.ac.uk/id/eprint/158385

Actions (repository staff only)

Edit Item